Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA cut from Prop 65

This article was originally published in The Rose Sheet

Executive Summary

Diethanolamine will not be listed under Prop 65, California's Office of Environmental Health Hazard Assessment announces March 7. Based upon public comments, OEHHA concludes "it is not clear that the scientific criteria for listing under the authoritative bodies have been met." Office determined sufficient criteria to propose listing the ingredient in 1999 despite attempts by the Cosmetic, Toiletry & Fragrance Association to oppose the listing. Decision coincides with recent recommendation by National Toxicology Program Board of Scientific Counselors subcommittee not to include DEA in NTP's upcoming 11th Report on Carcinogens (1"The Rose Sheet" Nov. 25, 2002, p. 5)...

You may also be interested in...



DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel

Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

RS011043

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel